CP and non-small cell lung carcinoma: A panel of two serum APPs, namely HP and CP, provides a clinically relevant pretherapeutic tool to predict the efficiency of PD-1/PD-L1 checkpoint inhibitor therapy as displayed in the progression-free survival of 139 NSCLC patients.